Following ESMO 2023,Erika P. Hamilton, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent clinical trial data in breast cancer.
EP. 1: KEYNOTE-756: Pembrolizumab Plus Chemo in Early-Stage ER+/HER2- Breast Cancer
Erika P. Hamilton, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data from KEYNOTE-756 investigating pembrolizumab plus chemotherapy in early-stage ER+/HER2- breast cancer.
EP. 2: TROPION-Breast01: Dato-DXd in Metastatic HR+/HER2- Breast Cancer
Experts on breast cancer review recent data updates from TROPION-Breast01 on Dato-DXd (datopotamab deruxtecan) in metastatic HR+/HER2- breast cancer.
EP. 3: KEYNOTE-522: Pembrolizumab in Triple-Negative Breast Cancer
Erika P. Hamilton, MD, and the Oncology Brothers offer clinical insights on recent data from KEYNOTE-522 on pembrolizumab in patients with triple-negative breast cancer.
EP. 4: Closing Thoughts on Data Updates From ESMO 2023
Following their review of data presented at ESMO 2023, the Oncology Brothers offer their key takeaways on the evolving breast cancer treatment landscape.
2 Clarke Drive Cranbury, NJ 08512